Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.41 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.41 |
| ▸ | HTR1A | P08908 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.40 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.40 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25189588 | 0.94 | IDO1 (0.43) | IDO1ALDH1A1LMNAL3MBTL1HTT | |
| SCHEMBL1697825 | 0.88 | IDO1 (0.46) | IDO1ALDH1A1LMNAL3MBTL1ADRA1A | |
| Hydrochloric Acid SCHEMBL20843623 | 0.86 | IDO1 (0.47) | IDO1ADRA1A | |
| SCHEMBL9261609 | 0.85 | IDO1 (0.49) | IDO1ALDH1A1LMNAL3MBTL1HTT | |
| SCHEMBL9167813 | 0.81 | IDO1 (0.49) | IDO1ALDH1A1LMNAL3MBTL1HTT | |
| SCHEMBL1756937 | 0.81 | IDO1 (0.49) | IDO1ALDH1A1LMNAL3MBTL1HTT | |
| SCHEMBL9159886 | 0.81 | IDO1 (0.49) | IDO1ALDH1A1LMNAL3MBTL1HTT | |
| SCHEMBL1722308 | 0.75 | GRIN2D (0.41) | — | |
| SCHEMBL7431326 | 0.75 | GRIN2D (0.41) | — | |
| SCHEMBL22975933 | 0.75 | HTR2C (0.40) | TAS1R3TAS1R1TAS1R2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024015731-A1 | FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF KRAS G12V MUTANTS | INCYTE CORPORATION (US) | 2024-01-18 | — | — | WO | claimed |
| US-20230226040-A1 | COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR | INCYTE CORPORATION | 2023-07-20 | — | — | US | claimed |
| CN-113668261-B | Dyeing liquid for optical resin and application method thereof | 拓烯科技(衢州)有限公司 | 2023-07-07 | — | — | CN | claimed |
| CN-113668261-A | Dyeing liquid for optical resin and application method thereof | 拓烯科技(衢州)有限公司 | 2021-11-19 | — | — | CN | claimed |
| EP-1184034-A2 | Oral drug composition containing a verapamil derivative as a drug-absorption promotor | Hanmi Pharm. Co., Ltd. (KR) | 2002-03-06 | — | — | EP | claimed |
| WO-2026090323-A1 | COMBINATION THERAPY USING A KRAS G12D INHIBITOR, AND A NUCLEOSIDE ANALOG, AND/OR A MICROTUBULE INHIBITOR AND ITS USE IN THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2026090333-A1 | COMBINATION USING A KRAS G12D INHIBITOR AND CHEMOTHERAPY COMBINATIONS AS WELL AS THEIR USE IN THE TREATMENT OF CANCER | INCYTE CORPORATION (US) | 2026-04-30 | — | — | WO | disclosed |
| WO-2025080593-A1 | COMBINATION THERAPY USING A KRAS G12D INHIBITOR AND PD-1 INHIBITOR OR PD-L1 INHIBITOR | INCYTE CORPORATION (US) | 2025-04-17 | — | — | WO | disclosed |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | VALO HEALTH, INC. (US) | 2024-12-10 | — | — | US | disclosed |
| US-12030883-B2 | Hetero-tricyclic compounds as inhibitors of KRAS | INCYTE CORPORATION (US) | 2024-07-09 | — | — | US | disclosed |
| CN-118265700-A | Substituted naphthyridinone derivative, pharmaceutical composition and application thereof | 上海海雁医药科技有限公司 | 2024-06-28 | — | — | CN | disclosed |
| WO-2024024508-A1 | COMPOSITION, FILM, OPTICAL FILTER, SOLID STATE IMAGING DEVICE, IMAGE DISPLAY DEVICE, INFRARED RADIATION SENSOR, AND METHOD FOR PRODUCING CAMERA MODULE | 富士フイルム株式会社 | 2024-02-01 | — | — | WO | disclosed |
| EP-0150192-A4 | BICYCLIC BENZENOID AMINOALKYLENE ETHERS AND THIOETHERS. | RORER INTERNAT OVERSEAS INC (US) | 1985-09-16 | — | — | EP | disclosed |
| EP-0150192-A1 | BICYCLIC BENZENOID AMINOALKYLENE ETHERS AND THIOETHERS. | RORER INT OVERSEAS (US) | 1985-08-07 | — | — | EP | disclosed |
| US-4529723-A | Gastrointestinal disorders; antiulcer agents | WILLIAM H. RORER, INC. (US) | 1985-07-16 | — | — | US | disclosed |
| US-4486428-A | ANALGESICS, ANTIEMETICS | PFIZER INC. (US) | 1984-12-04 | — | — | US | disclosed |
| WO-1984004247-A1 | BICYCLIC BENZENOID AMINOALKYLENE ETHERS AND THIOETHERS, AND THEIR PHARMACEUTICAL USES | RORER INT OVERSEAS (US) | 1984-11-08 | — | — | WO | disclosed |
| EP-0089781-A2 | Bicyclic benzo fused compounds | PFIZER INC. (US) | 1983-09-28 | — | — | EP | disclosed |
| US-4013682-A | N-HYDROXY-AMIDINE COMPOUNDS | AKZONA INCORPORATED (US) | 1977-03-22 | — | — | US | disclosed |
| US-3978126-A | N-HYDROXY-AMIDINE COMPOUNDS | AKZONA INCORPORATED (US) | 1976-08-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12030883-B2 | Hetero-tricyclic compounds as inhibitors of KRAS | KRAS, NRAS, HRAS | IDO1 4614/4885ALDH1A1 3337/4885LMNA 2935/4885 |
| US-12162888-B2 | Carboxamides as ubiquitin-specific protease inhibitors | USP28, USP25, USP24 | IDO1 730/4885ALDH1A1 2167/4885LMNA 3132/4885 |
| US-20230226040-A1 | COMBINATION THERAPY COMPRISING AN FGFR INHIBITOR AND A KRAS INHIBITOR | KRAS, FGFR2, FGFR3 | IDO1 4799/4885ALDH1A1 1884/4885LMNA 4510/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.